Clinical Trial Update: Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety and immunogenicity of Hantaan and Puumala virus DNA vaccines for prevention of hemorrhagic fever with renal syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Fever with Renal Syndrome

Drugs mentioned

• Hantaan virus DNA vaccine
• Puumala virus DNA vaccine

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Hantaan Virus Nephropathy, Puumala Virus Nephropathy | Phase 2 | Status: UNKNOWN